Teva settles patent dispute with India's Aurobindo over its Austedo medicine | Seeking Alpha
Teva announces FDA approval of Austedo tablets for chorea associated with huntington's disease - Pharma Advancement
Austedo (deutetrabenazine): Basics, Side Effects & Reviews
Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington's Disease - Clinical Trials Arena
China Approves Austedo for Huntington's-related Chorea
Teva's Austedo is first 'heavy hydrogen' drug to win US FDA approval
Punit on Twitter: "#Austedo stellar Q2 sales reported by Teva on 5th Aug'20 Austedo net sales in FY19 stood $412M & continues to grow in H1FY20👇 Q2-17- $1 M Q2-18- $44 M
Teva Stock Offers Maximum Optimism For Investors (NYSE:TEVA) | Seeking Alpha
Israel's Teva gets green light from China on major treatment - www.israelhayom.com
Teva takes on Neurocrine with TD nod for Austedo | Fierce Pharma
FDA expands use of Austedo to tardive dyskinesia in adults
FDA approves Teva's Austedo for tardive dyskinesia - PharmaTimes
FDA approves first deuterated drug
Teva resolves patent dispute with Aurobindo pharma over Huntingtons disease drug AUSTEDO
Tardive Dyskinesia Treatment, Causes, & Symptoms
Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease — Hereditary Neurological Disease Centre
Teva's Austedo (deutetrabenazine) Receives the NMPA's Approval to Treat Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults
Teva launches first DTC for Austedo into competitive tardive dyskinesia 2-drug market | Fierce Pharma
Deutetrabenazine - Wikipedia
Austedo: Package Insert / Prescribing Information - Drugs.com
2020 Pharma Choice DTC/DTP Silver Winner Intouch Group and Teva | PM360
Teva Settles With Lupin Over Austedo Patent
